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Nicolas Blin,1 Richard Traineau,2 Stephanie Houssin,3 Regis Peffault de Latour,1
Anna Petropoulou,1 Marie Robin,1 Jeroˆme Larghero,4 Patricia Ribaud,1,5 Gerard Socie1,5,6Major ABO incompatibility between donor and recipient is not considered a barrier to successful allogeneic
hematopoietic stem cell transplantation (HSCT), even if it can be associated with several immunohemato-
logic complications. Nevertheless, conflicting data still exist as to its influence on graft-versus-host disease
(GVHD) incidence, relapse rate, and survival. To further investigate the relevance of ABO major mismatch
on transplantation outcome, we retrospectively analyzed results from 414 patients with major or major/mi-
nor ABO-mismatched bone marrow (BM), peripheral blood (PB), and cord blood (CB) allogeneic HSCT.
Transplantation outcome was assessed by comparison with results from a 395-patient ABO-compatible
population with similar characteristics. Median time to red cell transfusion independence was significantly
longer in ABO-incompatible BM recipients (median time, 63 days vs 41 days; P5.001), with faster disappear-
ance of antidonor IgM hemagglutinins in unrelated recipients (median time, 36 days vs 44 days; P5.03) and in
patients with grade$II acute GVHD (aGVHD) (median time, 35 days vs 59 days ; P 5 .001). In PB stem cell
(PBSC) and CB transplantation, erythroid reconstitution was not significantly delayed, regardless of donor
type or presence of aGVHD. A slight correlation between ABO incompatibility and GVHD incidence was
found in PBSC recipients when considering grade $II aGVHD incidence (63% in ABO-matched HSCT vs
83% in ABO-mismatched HSCT; P 5 .055), but this was not confirmed in multivariate analysis. In patients
with acute leukemia, multivariate analysis revealed an association between major ABO mismatch and de-
creased relapse rate with borderline statistical significance (hazard ratio, 0.65; P 5 .04). Major ABO incom-
patibility mainly, if not exclusively, affects red blood cell engraftment after BM transplantation. Somewhat
surprisingly, the graft-versus-plasma cell effect seems to be confined to this stem cell source.
Biol Blood Marrow Transplant 16: 1315-1323 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Acute graft-versus-host disease, Bone marrow, ABO incompatibility, Hematopoietic recov-
ery, Transfusion needs1AP-HP, Saint Louis University Hospital, Hematology
tment-Transplant Unit, 1 Avenue Claude Vellefaux,
Paris, France; 2Saint Louis University Hospital, Transfu-
epartment, 1 Avenue Claude Vellefaux, 75010 Paris,
e; 3Nantes University Hospital, Biostatistics Department,
e Alexis Ricordeau, 44093 Nantes, France; 4AP-HP, Saint
University Hospital, Cellular Engineering Unit, 1 Avenue
e Vellefaux, 75010 Paris, France; 5Denis Diderot Paris 7
rsity, Hayem Center, 1 Avenue Claude Vellefaux, 75010
France; and 6INSERM U728, University Institute of He-
ogy, Denis Diderot Paris 7 University, Paris, France.
isclosure: See Acknowledgments, page 1322.
dence and reprint requests: Gerard Socie, Service
atologie Greffe & Inserm U728, Hoˆpital Saint-Louis, 1
laude Vellefaux, 75010 Paris, France (e-mail: gerard.
sls.aphp.fr).
ecember 1, 2009; accepted March 22, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.03.021INTRODUCTION
In contrast to solid organ transplantation, alloge-
neic hematopoietic stem cell transplantation (HSCT)
can be performed across the ABO blood group barrier
[1]. ABO incompatibility between donor and recipient
occurs in 30%-40% of patients undergoing HSCT,
because ABO blood groups are inherited indepen-
dently from human leukocyte antigens [2].
Three groups of ABO mismatch can be distin-
guished in HSCT: minor, major, and bidirectional
ABO incompatibility. Minor ABO incompatibility
(eg, from an type-O donor to a type-A, -B, or -AB
recipient) is characterized by the ability of donor B
lymphocytes to produce antirecipient isoagglutinins.
In contrast, major ABO-incompatible HSCT (eg,
from a type-A, -AB, or -B donor to an type-O recipi-
ent) is characterized by the presence of preformed
antidonor isoagglutinins. In bidirectional ABO1315
1316 Biol Blood Marrow Transplant 16:1315-1323, 2010N. Blin et al.incompatibility (eg, type-A donor to a type-B recipi-
ent), a combination of both major and minor ABO
blood group barriers must be overcome.
Although ABO incompatibility between donor and
recipient does not represent a barrier to successful
HSCT, it is well established that major ABO incom-
patibility can lead to prolonged destruction of
donor-derived erythrocytes, with pure red blood cell
(RBC) aplasia and prolonged transfusion requirements
[3], despite such techniques as plasma exchange and
RBC depletion of the donor marrow [4,5]. Similarly,
minor ABO incompatibility can result in an
increased risk of delayed immune hemolysis [6,7],
which occurs in approximately 10%-15% of cases [1].
Mielcarek et al. [8] reported that the degree of ge-
netic disparity between donor and recipient, especially
in unrelated graft recipients, and graft-versus-host
disease (GVHD) can affect the rate of disappearance
of antidonor isohemagglutinins, suggesting a graft-
versus–plasma cell effect. More recently, Kimura
et al. [9] reported specific effects of major and minor
ABO incompatibility on transplantation-related mor-
tality and incidence of acute GVHD (aGVHD) in
recipients of bone marrow transplants (BMTs) from
unrelated donors. However, conflicting data still exist
about the influence of major ABO incompatibility on
GVHD incidence [8,10], hematologic recovery [11],
relapse rate [12,13], and survival [14-16], especially
with the use of alternative donor sources, such as
peripheral blood (PB) and cord blood (CB).
Allogeneic PB stem cell transplantation (PBSCT)
has been increasingly preferred over BMT because of
its more rapid hematologic recovery and potent graft-
versus-tumor effect in hematologic malignancies
[17,18]. However, to date, only a few studies have
addressed the impact of major ABO mismatch on
GVHD incidence and survival in PBSCT.
The aims of this single-center study were to (1) val-
idate the impact of major ABO mismatch and genetic
disparity on erythroid reconstitution in allogeneic
BMT; (2) investigate the role of major ABO incompat-
ibility on hematologic recovery, GVHD incidence,
relapse rate, and overall survival (OS) in PBSCT; and
(3) analyze these 4 parameters in CB transplantation
(CBT).MATERIALS AND METHODS
Patient Characteristics
The study included a total of 414 patients who un-
derwent HSCT at Saint Louis University Hospital,
Paris, between 1978 and 2005. Median follow-up was
76 months. Of the 414 patients, 226 underwent BMT,
138 underwent PBSCT, and 49 underwent CBT.
Among the ABO-mismatch population, patients
received a major (n 5 337; 81%) or major/minor(n5 77; 19%) ABO-mismatched allogeneic transplant
from a matched related donor (MRD; n 5 136; 33%)
or a matched unrelated donor (MUD; n 5 278;
67%). Myeloablative (MA) conditioning regimens in-
cluded fractioned total body irradiation (TBI)1 cyclo-
phosphamide (n 5 166; 40%) and busulfan 1
cyclophosphamide (n5 168; 41%). Nonmyeloablative
(NMA) regimens were all fludarabine-based, either
with (n 5 20; 5%) or without (n 5 60; 14%) 2 Gy
TBI. HSCT was performed for both malignant
(n5 296; 71%) and nonmalignant (n5 118; 29%) he-
matologic diseases, and GVHD prophylaxis was based
mainly on standard regimen with cyclosporine A (CsA)
1methotrexate (n5 312; 75%) after MA conditioning
and with cyclosporine A (CsA) 1 mycophenolate mo-
fetil (MMF; n 5 73 [18%]) after NMA conditioning.
Details regarding indications for HSCT, GVHD pro-
phylaxis, GVHD incidence, and other patient and
transplant characteristics are given in Table 1.
Transplantation outcomes were compared with
those from a 395-patient ABO-compatible population
with similar characteristics with respect to period of
transplantation, stem cell source, conditioning regi-
men, GVHD prophylaxis, and donor type (Table 2).Hemagglutinin Titer Monitoring and
Transfusion Policy
As described previously [8,19], posttransplantation
anti-A and anti-B isohemagglutinin IgG and IgM ti-
ters were followed weekly from day 14 post-HSCT
for each patient. For patients with an anti-A and/or
anti-B titer .1:128 during pretransplantation assess-
ment, IgG and IgM were evaluated twice weekly after
transplantation until achievement of titers below 1:16,
then weekly until their complete disappearance. Hem-
agglutinin titer quantification was followed until it was
undetectable for 2 consecutive weeks, except in pa-
tients with persistent RBC transfusion requirements.
All transfused packed RBCs and platelets were sep-
arated from plasma and irradiated at a dose of 30 Gy to
prevent the risk of acute transfusion-induced GVHD.
Whatever the period of transplant was, all patients re-
ceived recipient- or type-O RBCs as long as isoagglu-
tinins directed against the donor blood group
remained measurable. At that point, RBC transfusions
were switched to donor type.Statistical Analysis
OS within ABO compatibility groups for all stem
cell source and donor type was estimated by the
Kaplan-Meier method [20]. For survival analysis,
follow-up time was censored at the date of last contact
for surviving patients, and the log-rank test was used to
test the significance of differences [21], adjusting for
potential confounding variables (age, disease status,
Table 2. Characteristics of ABO-Matched and ABO-
Mismatched Populations
Parameter ABO Mismatch ABO Match P
Total, n (%) 414 (51) 395 (49) NA
Sex, % male 55 54 .42
Age, years, median (range) 25.3 (0.6-66) 28.6 (3-60) .35
Hematologic diagnosis, n (%)
AML 87 (12) 83 (10) .39
ALL 76 (9) 74 (9) .46
MDS 27 (3) 27 (3) .50
CML 84 (10) 84 (10) .30
SAA 45 (6) 45 (6) .42
PNH 6 (1) 5 (1) .41
Hodgkin 6 (1) 8 (1) .45
NHL 16 (2) 14 (2) .42
Fanconi anemia 37 (5) 34 (4) .50
Sickle cell anemia/thalassemia 10 (1) 10 (1) .41
Miscellaneous 20 (2) 11 (1) .21
Stem cell source, n(%)
BM 226 (27) 213 (26) .25
PBSC 138 (17) 135 (17) .37
CB (simple) 42 (5) 41 (5) .18
CB (double) 7 (1) 6 (1) .30
BM + CB 1 (1) 0 (0) .45
Conditioning regimen, n(%)
TBI/Cy 166 (21) 163 (20) .45
Bu/Cy 168 (20) 154 (19) .29
Other TBI-containing regimens 20 (2) 20 (2) .50
Other non–TBI-containing
regimens
60 (7) 58 (7) .35
Myeloablative 336 (41) 321 (40) .32
Nonmyeloablative 78 (10) 74 (9) .41
GVHD prophylaxis, n (%)
CsA-MTX 312 (38) 302 (37) .28
CsA alone 16 (2) 10 (1) .25
CsA-MMF 73 (9) 72 (9) .30
MMF-corticosteroids 7 (1) 7 (1) .43
MTX alone 6 (1) 4 (1) .26
Donor type
MRD 136 (17) 146 (18) .28
MUD 278 (34) 249 (32) .25
Period of transplantation
1978-1985 32 (4) 28 (3) .29
1985-1995 141 (17) 140 (17) .42
1995-2005 241 (30) 227 (28) .38
aGVHD, n(%)
Grade 0-I 110 (14) 144 (17) .16
Grade II-IV 304 (38) 251 (31) .06
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous
leukemia; SAA, severe aplastic anemia; PNH, paroxysmal nocturnal he-
moglobinuria; NHL, non-Hodgkin’s lymphoma; Cy, cyclophosphamide;
Bu, busulfan; CsA, cyclosporine A; MTX, methotrexate; MRD, matched
related donor; MUD, matched unrelated donor; BM, bone marrow; CB,
cord blood.
Table 1. ABO-Mismatched Transplantations: Patients and
Transplant Characteristics
Parameter MRD MUD P
Total, n (%) 136 (33) 278 (67) NA
Sex, % male 58 54 .68
Age, years, median (range) 26.2 (3-55) 24.3 (0.6-66) .75
Hematologic diagnosis, n (%)
AML 30 (22) 57 (21) .65
ALL 24 (18) 52 (19) .76
MDS 9 (7) 18 (6) .60
CML 31 (23) 53 (19) .32
SAA 14 (10) 31 (11) .40
PNH 3 (2) 3 (1) .86
Hodgkin lymphoma 2 (1) 4 (1) .90
NHL 5 (4) 11 (4) .76
Fanconi anemia 11 (8) 26 (9) .67
Sickle cell anemia/thalassemia 3 (2) 7 (3) .80
Miscellaneous 4 (3) 16 (6) .26
Stem cell source, n (%)
BM 72 (53) 154 (55) .43
PBSC 56 (41) 82 (29) .05
CB (simple) 8 (6) 34 (12) .16
CB (double) 0 (0) 7 (3) .65
BM + CB 0 (0) 1 (1) .90
Conditioning regimen, n (%)
TBI/Cy 52 (38) 114 (41) .35
Bu/Cy 58 (43) 110 (40) .42
Other TBI-containing regimens 7 (5) 13 (4) .60
Other non–TBI-containing
regimens
19 (14) 41 (15) .45
Myeloablative 110 (81) 226 (81) .90
Nonmyeloablative 26 (19) 52 (19) .85
GVHD prophylaxis, n (%)
CsA-MTX 100 (74) 212 (76) .65
CsA alone 6 (4) 10 (4) .80
CsA-MMF 23 (17) 50 (18) .65
MMF-corticosteroids 3 (2) 4 (1) .87
MTX alone 4 (3) 2 (1) .80
aGVHD, n (%)
Grade 0-I 66 (49) 44 (16) .01
Grade II-IV 70 (51) 234 (84) .01
ABO incompatibility, n (%)
Major mismatch 108 (79) 229 (82) .26
Major/minor mismatch 28 (21) 49 (18) .40
Hemagglutinin type, n (%)
Anti-A 89 (65) 185 (67) .41
Anti-B 44 (32) 86 (31) .50
Anti-A + anti-B 3 (2) 7 (2) .90
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous
leukemia; SAA, severe aplastic anemia; PNH, paroxysmal nocturnal he-
moglobinuria; NHL, non-Hodgkin lymphoma; Cy, cyclophosphamide;
Bu, busulfan; CsA, cyclosporine A; MTX, methotrexate.
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mismatch, and year of transplantation). Incidences of
aGVHD, relapse rate, and attainment of hemaggluti-
nin titer endpoint were calculated using cumulative in-
cidence estimates [21].
Hematologic endpoints were defined as follows:
 Engraftment: sustained absolute neutrophil count
(ANC) $0.5 109/L for at least 5 days with no use
of granulocyte colony-stimulating factor
 RBC transfusion independence: absence of transfu-
sion needs for at least 7 days with sustained hemo-
globin level $8 g/dL Platelet recovery: platelet count$ 20 109/L with no
transfusion needs for at least 72 hours
Univariate analysis was performed using c2 and
Mann-Whitney U tests, whereas multivariate analysis
was done using Cox proportional hazard regression
models [22], with assessment of age, disease status
at time of transplantation, donor type, stem cell
source, and ABO major mismatch on 3-year overall
survival, incidence of aGVHD and chronic GVHD
(cGVHD), and relapse rate. All reported P values are
2-sided, and P\ .05 is considered to indicate statistical
significance.
1318 Biol Blood Marrow Transplant 16:1315-1323, 2010N. Blin et al.RESULTS
Impact of ABO Major Incompatibility on
Erythroid Reconstitution in BMT Recipients
To validate the relevance of our 2 populations
(ABO-mismatched and control ABO-matched), we
first selected patients undergoing BMT and deter-
mined the impact of ABO incompatibility on erythroid
reconstitution based on RBC transfusion require-
ments. As shown in Table 2, the 2 populations ap-
peared to have similar characteristics, especially in
terms of stem cell source, conditioning regimen, donor
type, period of transplantation, and GVHD incidence
(P . .05 for each parameter).
In ABO-incompatible marrow recipients, median
time to RBC transfusion independence was signifi-
cantly longer (median time, 63 days vs 41 days; P 5
.001) (Figure 1). This difference appears to be inde-
pendent of the amount of cells infused during trans-
plantation, with a median number of CD341 cells of
2.4 106/kg in ABO-mismatched patients and 2.6 106/
kg in control ABO-matched patients (P 5 .28).Impact of Donor Type on Transfusion Needs and
Antidonor Hemagglutinin Disappearance
Kinetics in the ABO-Mismatched Population
To confirm the role of donor type in erythroid re-
covery after BMT, we evaluated RBC transfusion
needs after MRD and MUD HSCT in both ABO-
matched and ABO–major mismatched patients. In
the MRD population, the mean number of RBC packs
transfused was significantly greater in the ABO-
mismatched population than in the ABO-matched
population (13 vs 6; P 5 .01), but this difference did
not reach statistical significance in the MUD popula-
tion (12 vs 14; P 5 .22). These results are given in
Table 3.
We then evaluated the role of genetic disparity on
erythroid reconstitution in the same population; 154Figure 1. Probability of RBC transfusion independence according to
time after transplantation in ABO-matched and major ABO-
mismatched BMTrecipients.patients in the ABO-major mismatched group received
a transplant from a MUD, compared with 72 from an
MRD. For the 2 groups, we determined the number of
days posttransplantation required to reach undetect-
able antidonor IgM hemagglutinins. The disappear-
ance of antidonor IgM hemagglutinins was
significantly faster in MUD recipients (median time,
36 days vs 44 days; P 5 .03) (Figure 2).
We also analyzed the correlation between the de-
gree of HLA matching and RBC engraftment in this
MUD population. Among the 154 patients receiving
ABO-major mismatched BM from an MUD donor,
35 were antigen-matched and 119 were allele-
matched. Among the 119 patients with allele-
matched BMT, the majority (n 5 87; 73%) received
a 10/10 matched transplant, whereas 20 (17%)
received a 9/10 matched transplant and 12 (10%) re-
ceived a 8/10 matched transplant. When considering
the delay after transplantation in reaching undetect-
able antidonor IgM hemagglutinins in those sub-
groups, we found a trend of shorter time for antigen-
matched transplants compared with allele-matched
transplants, but the difference did not attain statistical
significance (32 days vs 36 days; P 5 .07). Comparing
the 3 different populations according to degree of
HLA allele matching (ie, 10/10, 9/10, and 8/10) re-
vealed no significant difference, because of the small
size of the corresponding subgroups (data not shown).
We investigated the effect of antithymocyte glob-
ulin (ATG) administration as part of the conditioning
regimen. Among the 154 patients in the MUD group,
102 (66%) received ATG, and 52 (34%) did not. The
median time to disappearance of antidonor IgM hem-
agglutinins was not significantly influenced by the use
of ATG (34 days vs 37 days; P 5 .16).Impact of Allogeneic Effect on Hemagglutinin
Titer Clearance
After confirming the impact of donor type on the
kinetic of antidonor IgM disappearance and RBC
transfusion requirements, we verified the role of the al-
logeneic effect on the speed of clearance of hemagglu-
tinin titers in the MUD group. For that purpose, in
both the MRD and MUD groups, we compared the
median time to reach undetectable antidonor IgM ac-
cording to aGVHD occurrence. In the MRD group,
this time was significantly shorter in patients with
grade II-IV aGVHD than in those with grade 0-I
aGVHD (57 vs 78 days; P 5 .001; relative risk [RR]
5 1.92). In the MUD group, no significant difference
was seen between these 2 groups (46 days vs 59 days;
P 5 .06; RR 5 1.21).
We also investigated the impact of grade II-IV
aGVHD on the kinetics of transfusion independence
(Figures 3 and 4). In the MRD group, the median
time to RBC transfusion independence was
Table 3. Median Number of RBC Packs Transfused among ABO-Mismatched BM Recipients with MRDs and MUDs
Stem Cell Source Donor Type ABO Compatibility n
RBC Packs
Transfused, Median (Range) Univariate RR P value 95% CI
BM MRD ABO match 78 6 (0-26) 1.0 NA NA
ABO mismatch 72 13 (2-92) 1.86 0.01 1.54-2.10
MUD ABO match 135 14 (0-44) 1.0 NA NA
ABO mismatch 154 12 (4-32) 0.95 0.22 0.80-1.05
BM indicates bone marrow; MRD, matched related donor; MUD, matched unrelated donor.
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aGVHD compared with those with grade 0-I aGVHD
(42 days vs 80 days; P5 .001). Of the MRD recipients
with grade II-IV aGVHD (n 5 70), only 7 patients
(10%) died before day 1100 posttransplantation.
When those patients were excluded from the analysis,
the difference in median time to RBC transfusion inde-
pendence remained significant between the 2 groups
(45 days vs 80 days; P 5 .002). Fourteen patients pre-
sented with additional causes of anemia (9 with severe
bleeding, 3 with drug-induced acute hemolysis, and 2
with severe fungal infection), and were excluded
from the analysis.
In the MUD group, there was no significant differ-
ence between patients with grade 0-I aGVHD and
those with grade II-IV aGVHD (35 days vs 60 days;
P 5 .08).
Our evaluation of ABO-major mismatch on ery-
throid and hematopoietic reconstitution in both
PBSCT and CBT revealed no significant impact using
these cell sources. These results are summarized in the
Supplemental Material.
Correlation between ABO Incompatibility and
GVHD Incidence
The probability of aGVHD was compared be-
tween the ABO-matched and ABO-mismatched trans-
plants for the 3 different stem cell sources. A separate
analysis was performed after exclusion of patients
with bidirectional ABO incompatibility in subgroupsFigure 2. Probability of anti-donor IgM disappearance according to
time after transplantation in ABO-mismatched transplants with MRDs
and MUDs.in which significant difference has been observed
(Table 4).
Among BM recipients, overall incidence of grade
$2 aGVHD was similar in ABO-matched and ABO-
mismatched transplants (72% [n 5 154] and 76% [n
5 172]; P5 .19). No difference was observed between
the MRD and MUD groups with ABO-mismatched
transplants (data not shown).
We assessed the incidence of aGVHD in the group
of PBSC recipients similarly. Analysis performed after
exclusion of patients with major/minor mismatch
(n 5 77) showed a tendency toward higher aGVHD
incidence in ABO-mismatched transplants (83%, vs
63% in ABO-matched; P 5 .05). This borderline sta-
tistically significant difference was observed in both
transplants from MRDs (46% vs 62%; P 5 .05) and
those from MUDs (68% vs 83%; P 5 .04). No differ-
ence in GVHD prophylaxis or conditioning regimen
was observed in those 2 groups (Tables 1 and 2).
In CBT recipients, analysis of transplants from
both the MRD and MUD groups did not appear to
be feasible, because of the small number of patients.Impact of ABO Major Incompatibility on
Relapse Rate
The risk of relapse was evaluated after selection of
patients undergoing HSCT for a malignant hemato-
logic disease. Hematologic malignancies represented
74% (n 5 292) of ABO-matched transplants and
71% (n 5 296) of ABO-mismatched transplants
(Tables 1 and 2).Figure 3. Probability of transfusion independence posttransplantation
among ABO-mismatched BMT recipients (MRDs) according to GVHD
occurrence.
Figure 4. Probability of transfusion independence posttransplantation
among ABO-mismatched BMT recipients (MUDs) according to GVHD
occurrence.
1320 Biol Blood Marrow Transplant 16:1315-1323, 2010N. Blin et al.Among BMT recipients, the relapse rate was 38%
(n 5 58) in ABO-matched transplants and 34% (n 5
53) in ABO-mismatched transplants (P 5 .065).
Analysis of the MRD and MUD groups for both
ABO-matched and ABO-mismatched transplants
demonstrated no significant difference in relapse
risk (40% vs 43% in the MRD group [P 5 .11] and
33% vs 36% in the MUD group [P 5 .08]).
In both the PBSCT and CBT recipients, the re-
lapse rate did not appear to be different in ABO-
matched and ABO-mismatched transplants. Only
a borderline statistical significance was observed in
the PBSCT group, with a relapse rate of 41% (n 5
45) in the ABO-matched group and 35% (n 5 37) in
the ABO-mismatched group (P 5 .055).OS
OS was analyzed by comparing ABO-matched and
ABO-mismatched transplants for BMT, PBSCT, and
CBT recipients only in patients treated for hemato-
logic malignancies. The median follow-up time for
surviving patients was 76 months for MRDs (range,
26-245 months) and 68 months for MUDs (range,
21-228 months).
OS according to stem cell source is summarized in
Table 5. In BMT recipients, there was no significant
difference in overall survival at 5 years between the
MRD group (51% vs 49%; P 5 .18) and the MUDTable 4. Grade $II aGVHD Incidence in ABO-Matched and -Mism
Stem Cell Source ABO Compatibility n
Gra
aGVH
BM ABO match 213 15
ABO mismatch 226 17
PBSCs ABO match 135 8
ABO mismatch 138 11
CB ABO match 47 1
ABO mismatch 50 1
aGVHD indicates acute graft-versus-host disease; BM, bone marrow; PBSCs,group (38% vs 33%; P 5 .08). In PBSCT recipients,
similar nonsignificant trends were found (MRD and
MUD overall survival of 42 vs 46 months [P 5 .08]
and 30 vs 38 months [P 5 .055] according to ABO
match, respectively). Among CBT recipients, median
overall survival was 20 months (n 5 30) for ABO-
matched transplants and 21 months (n 5 35) for
ABO-mismatched transplants (P 5 .06). Subgroup
analysis in MRDs and MUDs could not be performed
because of the small number of patients in this
population.
Multivariate Analysis
We used Cox proportional hazard regression
models to assess the impact of different transplantation
parameters on 3-year OS, aGVHD and cGVHD inci-
dence, and relapse rate. Among the parameters tested,
we considered age, disease type, and status at time of
transplantation, donor type, stem cell source, condi-
tioning regimen, GVHD prophylaxis, ABO major
mismatch, and hemagglutinin subtype. For OS and re-
lapse risk, we considered grade $II aGVHD and
cGVHD as time-dependent covariates. Moreover, re-
lapse risk assessment in this multivariate analysis con-
sidered only patients with acute myelogenous or
lymphoblastic leukemia, given the high heterogeneity
of hematologic malignancies included in the study.
When considering 3-year OS, no impact of ABO
major mismatch or hemagglutinin subtype on survival
was identified (hazard ratio [HR], 1.07 [P 5 .45] and
0.97 [P5 .35], respectively). Similarly, ABO mismatch
did not significantly influence the aGVHD rate (odds
ratio [OR], 1.24; P 5 .09). The sole parameter influ-
enced by donor/recipient ABO mismatch was 3-year
relapse risk (OR, 0.65; P 5 .04). This parameter also
was influenced by cGVHD (OR, 0.55; P 5 .035).
The results of multivariate analysis are summarized
in Table 6.DISCUSSION
The aim of this single-center retrospective study
was to evaluate in a large cohort of patients the impact
of donor/recipient major ABO mismatch on GVHD
incidence, OS, and relapse risk according to stem cellatched Transplants According to Stem Cell Source
de $II
D, n (%) Univariate RR P Value 95% CI
4 (72) 1.0 NA NA
2 (76) 1.15 .19 1.08-1.28
5 (63) 1.0 NA NA
3 (82) 2.10 .01 1.8-3.1
2 (26) 1.0 NA NA
9 (38) 1.21 .15 1.12-1.40
peripheral blood stem cells; CB, cord blood.
Table 5. Median Overall Survival in ABO-Matched and ABO-
Mismatched Transplants According to Stem Cell Source
Stem
Cell Source
ABO
Compatibility
Hematologic
Malignancies, n (%)
Median Overall
Survival, Months P
BM ABO match 153 (72) 38 NA
ABO mismatch 156 (69) 41 .07
PBSCs ABO match 109 (81) 34 NA
ABO mismatch 105 (76) 39 .055
CB ABO match 30 (64) 20 NA
ABO mismatch 35 (70) 21 .35
All cohort ABO match 292 (74) 34 NA
ABO mismatch 296 (71) 37 .06
BM indicates bone marrow; PBSCs, peripheral blood stem cells; CB,
cord blood.
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received homogeneous management in terms of condi-
tioning regimen, indications for transplantation,
GVHD prophylaxis, immunohematologic monitor-
ing, and transfusion policies. Moreover, PBSCT and
CBT recipients were included in the study, so that
our series represents, to the best of our knowledge,
one of the largest to date on the impact of major
ABO mismatch in patients undergoing allogeneic
HSCT.
To evaluate the relevance of our population selec-
tion, we first assessed the impact of ABO mismatch on
erythroid reconstitution in BMT recipients. As de-
scribed previously [8], we found a significantly longer
time to transfusion independence in the ABO-
mismatch population. The level of genetic disparity
between donor and recipient also appeared to have
an impact on both antidonor IgM hemagglutinin dis-
appearance and RBC pack transfusion needs with
faster disappearance of antidonor IgM hemagglutinins
in MUD recipients and MRD recipients with grade
$II aGVHD.
The median time to reach undetectable antidonor
IgM tends to be shorter in MUD recipients with grade
II-IV aGVHD compared with those with grade 0-I
aGVHD, but the difference does not reach statistical
significance, as reported previously [8]. The lack ofTable 6. Multivariate Analysis of Factors Influencing Survival,
aGVHD, and Relapse Risk
Parameter HR 95% CI P
3-year overall
survival
Age >35 2.56 1.95-3.35 .01
No CR at transplantation 2.75 2.10-3.75 .005
Grade $II aGVHD 2.25 1.85-3.05 .008
aGVHD
incidence
Age >35 2.18 1.65-2.75 .02
Unrelated donor 3.24 2.65-4.15 .001
Peripheral blood 1.78 1.25-2.95 .03
Relapse risk Donor/recipient
ABO mismatch
0.65 0.58-0.72 .04
cGVHD 0.55 0.43-0.72 .035
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; CR, complete remission.correlation in this group was not related to a lack of
power because of small sample size. We also investi-
gated whether the higher mortality rate in MUD re-
cipients with grade $II aGVHD could account for
this lack of difference. The mortality rate before day
1100 after MUD HSCT was 14% (n5 33) in patients
with grade$II aGVHD, compared with 6% (n5 1) in
those without grade$II aGVHD. Excluding these pa-
tients with early death did not change the results in
term of transfusion needs or antidonor IgM hemagglu-
tinin clearance.
The hypothesis of a potential impact of early death
rate in MRD patients with grade II-IV aGVHD on re-
sults has been verified. In 70 patients with grade II-IV
aGVHD, only 10% (n 5 7) died before day 1100,
compared with 6% (n 5 4) of those with grade\II
aGVHD. After excluding those patients with early
death, the difference in median time to RBC transfu-
sion independence remained significant between the
2 groups (45 days vs 80 days; P 5 .002).
When evaluating the impact of aGVHD on anti-
donor hemagglutinin titer clearance, we assessed the
impact of conditioning regimen, particularly the use
of ATG. ATG is known to target B cells and plasma
cells through a complement-independent apoptosis
mechanism [23,24]. ATG was given as GVHD
prophylaxis in 102 of 154 patients receiving a MUD
transplant with ABO-mismatched BM (66%). A simi-
lar median time to disappearance was found in patients
who received ATG and those who did not receive
ATG, suggesting that the role of an allogeneic effect
against host plasma cells is independent of ATG use.
We also identified a direct correlation between
antidonor IgM hemagglutinin clearance and RBC
transfusion needs in this ABO-mismatched population
receiving MRD transplants by excluding from the
analysis all patients with confounding causes of severe
anemia. Median time to RBC transfusion indepen-
dence was confirmed to be shorter in MRD recipients
with grade II-IV aGVHD, with this difference inde-
pendent of all associated conditions. These results
are consistent with those of previous studies
[1,3,8,25] and give another argument to the
hypothesis of a graft-versus-plasma cell effect in
BMT recipients.
But, when considering erythroid reconstitution in
PBSCT and CBT recipients, we found any impact of
major ABO incompatibility, regardless of hemaggluti-
nin type and number of nucleated cells in the trans-
plant. The majority of PBSCT recipients received
nonmyeloablative conditioning, and more than half
of the patients (70/138) experienced prolonged ery-
throid reconstitution with this type of conditioning,
in agreement with some [26-28], but not all [29], re-
ports. The lack of impact of ABO mismatch in those
transplants might result from the immunosuppressive
treatment based on association of CsA with MMF,
1322 Biol Blood Marrow Transplant 16:1315-1323, 2010N. Blin et al.because MMF has the ability to suppress B cell anti-
body production, and thus might possibly prevent
pure red cell aplasia after low-dose conditioning [30].
Most of the CBT recipients (84%; 42/50) received
standard conditioning with GVHD prophylaxis based
mainly on CsA-MMF. The reasons for the absence of
major ABO- mismatch impact on erythroid recovery in
this population are unclear, but our results should be
interpreted with caution because of the sample size–
limited statistical power of the analysis. Thus, some-
what surprisingly, the graft-versus–plasma cell effect
seems to be confined to BMT either directly or indi-
rectly through aGVHD.
Our study revealed no impact of major ABO in-
compatibility on neutrophil or platelet recovery re-
gardless of donor type, conditioning regimen, and
stem cell source. These results are consistent with pre-
vious studies that reported no impact of major ABO
mismatch on engraftment [27,31].
In particular, we identified 5 patients (4 BMT
recipients and 1 PBSCT recipient) with pure RBC
aplasia and very prolonged RBC transfusion needs
(time to transfusion independence ranging from day
1245 to day 1545 posttransplantation), with one pa-
tient still dependent on packed RBC transfusion at
time of follow-up (25 months). All patients underwent
HSCT after removal of ABO-incompatible RBCs fol-
lowing current methods for erythrocyte depletion in
donor/recipient major ABO-incompatible allogeneic
HSCT [4,5]. Two patients became transfusion-
independent after rituximab infusion, confirming the
use of this anti-CD20 monoclonal antibody in this sit-
uation [32,33]. One patient recovered from pure RBC
aplasia after plasmapheresis, and another did so after
high-dose dexamethasone, as described previously
[34,35]. The only patient with persistent RBC
transfusion needs failed to respond to the
aforementioned treatments followed by 3 doses of
donor lymphocyte infusion, with no occurrence of
aGVHD. She received 2 units of packed RBCs every
other week, and had a reticulocyte count\10 109/L
at day 1750 posttransplantation.
In this study, ABO incompatibility did not signifi-
cantly impair survival or aGVHD rates. As expected,
cGVHD represented the major parameter associated
with reduced relapse risk in multivariate analysis
(HR, 0.55; P5 .035). The association of ABO incom-
patibility and decreased relapse rate should be inter-
preted with extreme caution, however (HR, 0.65;
P 5 .04). Note that this statistical significance has
been identified only in patients with acute leukemia af-
ter exclusion of other malignancies. Indeed, compari-
son between acute leukemias, CML, MDS, and
lymphomas does not appear to be feasible because of
the high heterogeneity in relapse risk stratification at
the time of transplantation. When focusing only on
BMT recipients for relapse rate in patients with acuteleukemia, no effect was found in ABO-mismatched
transplants compared with ABO-matched transplants
(36% vs 39%; P 5 .12). Moreover, during our rela-
tively long study period, new risk factors have emerged
(eg, flt3 ITD in AML and major role of cytogenetic
classification in MDS and myeloma) that could not
be included in these retrospective analyses.
Finally, we specifically explored correlation be-
tween cGVHD incidence and major ABO incompati-
bility, because little data are available on this subject.
The only risk factor identified in multivariate analysis
for cGVHD was PBSCT, with no effect of major ABO
mismatch (HR, 1.04; P 5 .35; data not shown). This
absence of correlation between chronic GVHD and
major ABO mismatch might be linked to ‘‘donor-
directed’’ instead of ‘‘host-directed’’ allogeneic activity
in this situation, with cGVHD requiring sustained
alloreactivity against minor histocompatibility anti-
gens, which is more likely to occur in minor ABO-
mismatched transplants.
In summary, in our experience, major ABO incom-
patibility leads mainly to delayed RBC recovery after
BMT, but not after PBSCT or CBT. Major ABO mis-
match does not seem to have a significant effect on
other major outcomes after allogeneic HSCT, such
as aGVHD and cGVHD incidence, relapse rate, and
OS regardless of the stem cell source. Therefore,
whenever feasible, major ABO-mismatched donors
should be avoided in BMT recipients, to prevent de-
layed erythroid recovery with prolonged RBC transfu-
sion needs and impaired quality of life.ACKNOWLEDGMENTS
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